Adeona Becomes Synthetic Biologics, Inc. -- New Name Reflects Biotechnology Company Focus on the Emerging Field of Synthetic Biologics -- -- New NYSE Amex Ticker Symbol: SYN -- PR Newswire ANN...
Adeona CEO to Present at the Harvard Investors Group Forum PR Newswire ANN ARBOR, Mich., Feb. 9, 2012 ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN...
Adeona Appoints C. Evan Ballantyne as Chief Financial Officer -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to Emerging Synthetic Biologics Company -- PR Newswire ANN...
Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus -- Adeona Chairman, Jeff Riley, Appointed New...
Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis PR Newswire ANN ARBOR, Mich., Jan. 19, 2012 ANN ARBOR, Mich., Jan. 19, 2012...
Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development -- Name Change Reflects Primary...
Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator -- PNA Center for Neurological Research Clinical Study Results Presented at the 22nd International Symposium on...
Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension PR Newswire ANN ARBOR, Mich., and GERMANTOWN...
Adeona Reports Third Quarter 2011 Financial Results -- Clinical Trial for Cognitive Dysfunction in Multiple Sclerosis Recruiting Patients -- PR Newswire ANN ARBOR, Mich., Nov. 14, 2011 ANN ARBOR...
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research PR Newswire ANN ARBOR, Mich., Nov. 11, 2011 ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Symbole | Prix | Vol. |
---|---|---|
AAPYKurv Yield Premium Strategy Apple AAPL ETF | US$ 26,5099 (0,00%) | 0 |
AAPXT Rex 2X Long Apple Daily Target ETF | US$ 30,16 (0,00%) | 0 |
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026 | US$ 26,42 (0,00%) | 0 |
AAAUGoldman Sachs Physical Gold ETF Shares | US$ 26,33 (0,00%) | 0 |
AAAAlternative Access First Priority CLO Bond ETF | US$ 25,125 (0,00%) | 0 |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales